18F-labeled difluoroestradiols: Preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals

Yann Seimbille, Jacques Rousseau, F. Bénard, Catherine Morin, Hasrat Ali, George Avvakumov, Geoffrey L. Hammond, Johan E. van Lier

Research output: Contribution to journalArticleAcademicpeer-review

69 Citations (Scopus)

Abstract

A-ring fluorination of estradiol (ES) at position 2 or 4 decreases the rate of metabolism by blocking the formation of catechol estrogens, one of the major metabolic pathways of ES. We postulate that adding a 2- or 4-fluoro substituent to 16α-[18F]fluoroestradiol (FES), a positron emission tomography (PET) radiopharmaceutical used for estrogen receptor (ER) imaging, should prolong its blood circulation time, and thus, improve its localization in ER-rich target tissues. On such account, we prepared a series of FES derivatives substituted with a fluorine atom at C2 or C4, with or without an 11β-OMe group, and we tested their binding affinities for the ER and different serum proteins including rat alphafetoprotein (AFP) and human sex hormone-binding globulin (SHBG). Labeling at the 16α-position was accomplished via nucleophilic substitution with [18F]F- on the reactive 16β,17β-cyclic sulfate intermediates. Decay corrected yields varied between 30 and 50% for a total synthesis time of 120min, providing final products with specific activities >3000Ci/mmol. The 18F-labeled analogs were evaluated for their biodistribution in immature female rats. Substitutions with the 4-F have little effect on binding affinities. Addition of the 2-F diminishes ER and AFP-binding affinities while augmenting the affinity for the SHBG. Addition of the 11β-OMe decreases all binding affinities, particularly to AFP and SHBG. In contrast, biodistribution of the corresponding [16α-18F]fluoro analogs in immature female rats revealed that the presence of the 11β-OMe group improves ER-mediated uterus uptake, with the 4,16α-[16α-18F]difluoro-11β-methoxyestradiol showing the highest uptake values (15% ID at 1-h post-injection). These data suggest that the addition of both a 4-F and 11β-OMe group onto FES may provide an improved radiopharmaceutical for PET imaging of ER densities in breast cancer patients.

Original languageEnglish
Pages (from-to)765-775
Number of pages11
JournalSteroids
Volume67
Issue number9
DOIs
Publication statusPublished - Aug 2002
Externally publishedYes

Bibliographical note

© 2002 Elsevier Science Inc. All rights reserved.

Funding Information: Supported by the Canadian Institutes of Health Research (CIHR) grant MOP-44065 and the Canadian Breast Cancer Research Initiative (CBCRI) Grant 012301. FB is supported by CIHR under the clinician-scientist program and JEvL is the holder of the Jeanne and J.-Louis Lévesque Chair in Radiobiology. We are grateful to Jean-François Fisette, Hugo Flamand, Philippe Roby and Roger Bossé (BioSignal-Packard, Perkin Elmer, 1744 William, Montreal, Que., Canada H3J 1R4) for RBA analysis on purified ERα.

Fingerprint

Dive into the research topics of '18F-labeled difluoroestradiols: Preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals'. Together they form a unique fingerprint.

Cite this